Floatz Rating
B63/100
Confidence
Indicative
Sponsor
Deraya University
Modality
Small molecule
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
62High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07416409CT.gov Effectiveness, Safety, and Tolerability of Anti-HER2 Drugs as Targeted Therapy for Egyptian Patients With ERBB2-Positive Breast Cancer | — | Completed | — | — | — |
NCT04185649CT.gov The Efficacy and Safety of BAT8001 Injection for the Treatment of HER2-positive Advanced Breast Cancer | — | Unknown | — | — | — |
NCT03500380CT.gov A Study of RC48-ADC Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer With or Without Liver Metastases | — | Unknown | — | — | — |
NCT02362958CT.gov A Multi-Center Study of Lapatinib in Patients With Trastuzumab-refractory Metastatic Breast Cancer | — | Completed | — | — | — |
NCT01873833CT.gov Capecitabine, Cyclophosphamide, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With HER2-Positive Metastatic Breast Cancer | — | Terminated | — | — | — |
NCT01783756CT.gov Phase 1b/2 Trial Using Lapatinib, Everolimus and Capecitabine for Treatment of HER-2 Positive Breast Cancer With CNS Metastasis | — | Completed | — | — | — |
NCT01827163CT.gov Paclitaxel With Trastuzumab and Lapatinib in HER2-Positive Early Stage Breast Cancer | — | Completed | — | — | — |
NCT01808573CT.gov A Study of Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer Who Have Received Two or More Prior HER2 Directed Regimens in the Metastatic Setting | — | Completed | — | — | — |
NCT01622868CT.gov Whole-Brain Radiation Therapy or Stereotactic Radiosurgery With or Without Lapatinib Ditosylate in Treating Patients With Brain Metastasis From HER2-Positive Breast Cancer | — | Completed | — | — | — |
NCT01705340CT.gov Akt Inhibitor MK2206, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With Locally Advanced or Metastatic HER2-Positive Breast , Gastric, or Gastroesophageal Cancer That Cannot Be Removed By Surgery | — | Terminated | — | — | — |
Show 8 more trialsShow fewer
NCT01688609CT.gov Lapatinib Ditosylate, Trastuzumab, Paclitaxel, and Surgery in Treating Patients With Breast Cancer | — | Completed | — | — | — |
NCT01245205CT.gov Akt Inhibitor MK2206 in Combination With Lapatinib Ditosylate in Patients With Advanced or Metastatic Solid Tumors or Breast Cancer | — | Completed | — | — | — |
NCT01238029CT.gov Dose Finding Study for Combination of Capecitabine, Lapatinib and Vinorelbine in Metastatic Breast Cancer | — | Terminated | — | — | — |
NCT00684983CT.gov Capecitabine and Lapatinib Ditosylate With or Without Cixutumumab in Treating Patients With Previously Treated HER2-Positive Stage IIIB-IV Breast Cancer | — | Completed | — | — | — |
NCT00614978CT.gov Lapatinib and Temozolomide for the Treatment of Progressive Brain Disease in HER-2 Positive Breast Cancer | — | Completed | — | — | — |
NCT00496366CT.gov Capecitabine (Xeloda) and Lapatinib (Tykerb) as First-line Therapy in HER2/Neu-positive Breast Cancer | — | Terminated | — | — | — |
NCT00390455CT.gov Fulvestrant With or Without Lapatinib in Treating Postmenopausal Women With Stage III or Stage IV Breast Cancer That is Hormone Receptor-Positive | — | Completed | — | — | — |
NCT00098605CT.gov Lapatinib in Treating Brain Metastases in Patients With Stage IV Breast Cancer and Brain Metastases | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
65High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · HER2 Positive Breast Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Lapatinib (this asset) | Deraya University | P3 | B · 63 |
| Pertuzumab | SWOG Cancer Research Network | P4 | BB |
| Trastuzumab | SWOG Cancer Research Network | P4 | BB |
| Ribociclib | Danish Breast Cancer Cooperative Group | P3 | BB |
| Docetaxel | Ohio State University Comprehensive Cancer Center | P3 | BB |
| Vinorelbine Ditartrate | Fudan University | P3 | BB |
| Cyclophosphamide | National University Hospital, Singapore | P3 | BB |
| Capecitabine | MedSIR | P4 | BB |
| gb221 | Genor Biopharma Co., Ltd. | P3 | BB |
+42 more in the HER2 Positive Breast Carcinoma cohort
Other indications for Lapatinib
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Breast Carcinoma | — | P3 | BB · 67 |
| Male Breast Carcinoma | — | P3 | BB · 67 |
| Estrogen-Receptor Positive Breast Cancer | — | P3 | BB · 64 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Lapatinib in HER2 Positive Breast Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/lapatinib-her2-positive-breast-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →